Metastatic castration-resistant prostate cancer: advances in treatment and symptom management
T Kulasegaran, N Oliveira - Current Treatment Options in Oncology, 2024 - Springer
Opinion statement The management of metastatic castrate-resistant prostate cancer
(mCRPC) has evolved in the past decade due to substantial advances in understanding the …
(mCRPC) has evolved in the past decade due to substantial advances in understanding the …
Addressing the reciprocal crosstalk between the AR and the PI3K/AKT/mTOR signaling pathways for prostate cancer treatment
F Raith, DH O'Donovan, C Lemos, O Politz… - International Journal of …, 2023 - mdpi.com
The reduction in androgen synthesis and the blockade of the androgen receptor (AR)
function by chemical castration and AR signaling inhibitors represent the main treatment …
function by chemical castration and AR signaling inhibitors represent the main treatment …
[HTML][HTML] Overall survival update for patients with metastatic castration-resistant prostate cancer treated with capivasertib and docetaxel in the phase 2 ProCAID clinical …
SJ Crabb, G Griffiths, D Dunkley, N Downs, M Ellis… - European Urology, 2022 - Elsevier
Abstract The PI3K/AKT/PTEN pathway is frequently deregulated in metastatic castration-
resistant prostate cancer (mCRPC). ProCAID was a phase 2 trial assessing addition of the …
resistant prostate cancer (mCRPC). ProCAID was a phase 2 trial assessing addition of the …
[HTML][HTML] Exploring the role of PI3K/AKT/mTOR inhibitors in hormone-related cancers: A focus on breast and prostate cancer
M Wylaź, A Kaczmarska, D Pajor, M Hryniewicki… - Biomedicine & …, 2023 - Elsevier
Breast cancer (BC) and prostate cancer (PC) are at the top of the list when it comes to the
most common types of cancers worldwide. The phosphatidylinositol 3-kinase (PI3K)/protein …
most common types of cancers worldwide. The phosphatidylinositol 3-kinase (PI3K)/protein …
A compendium of Androgen Receptor Variant 7 target genes and their role in Castration Resistant Prostate Cancer
KJ Miller, I Henry, Z Maylin, C Smith… - Frontiers in …, 2023 - frontiersin.org
Persistent androgen receptor (AR) signalling is the main driver of prostate cancer (PCa).
Truncated isoforms of the AR called androgen receptor variants (AR-Vs) lacking the ligand …
Truncated isoforms of the AR called androgen receptor variants (AR-Vs) lacking the ligand …
Microwave triggered multifunctional nanoplatform for targeted photothermal-chemotherapy in castration-resistant prostate cancer
P Liu, Y Wu, X Xu, X Fan, C Sun, X Chen, J Xia, S Bai… - Nano Research, 2023 - Springer
Lacking a precise targeting strategy, castration-resistant prostate cancer (CRPC) is still hard
to be treat effectively. Exploring treatment options that can accurately target CPRC is an …
to be treat effectively. Exploring treatment options that can accurately target CPRC is an …
Pleckstrin-2 mediates the activation of AKT in prostate cancer and is repressed by androgen receptor
Phosphoinositide 3-kinase (PI3K)-AKT and androgen receptor (AR) pathways are commonly
activated in prostate cancers. Their reciprocal regulation makes advanced prostate cancers …
activated in prostate cancers. Their reciprocal regulation makes advanced prostate cancers …
Advances in the current understanding of the mechanisms governing the acquisition of castration-resistant prostate cancer
Y Mao, G Yang, Y Li, G Liang, W Xu, M Hu - Cancers, 2022 - mdpi.com
Simple Summary Castration-resistant prostate cancer (CRPC) is an advanced form of
prostate cancer with a low survival rate, as the CRPC patients only survive for 9–13 months …
prostate cancer with a low survival rate, as the CRPC patients only survive for 9–13 months …
Evodiamine as the Active Compound of Evodiae fructus to Inhibit Proliferation and Migration of Prostate Cancer through PI3K/AKT/NF‐κB Signaling Pathway
Y Lei, M Chan, H Liu, W Lyu, L Chen, Y Zhong… - Disease …, 2022 - Wiley Online Library
Evodiae fructus (EF) is a traditional Chinese medicine which is widely used for the treatment
of obesity, inflammation, cardiovascular disease, and diseases of the central nervous …
of obesity, inflammation, cardiovascular disease, and diseases of the central nervous …
Epithelial-mesenchymal transition: a fundamental cellular and microenvironmental process in benign and malignant prostate pathologies
AP Goncharov, N Vashakidze, G Kharaishvili - Biomedicines, 2024 - mdpi.com
Epithelial-mesenchymal transition (EMT) is a crucial and fundamental mechanism in many
cellular processes, beginning with embryogenesis via tissue remodulation and wound …
cellular processes, beginning with embryogenesis via tissue remodulation and wound …